Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Fineline Cube Jul 16, 2026
Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Fineline Cube Jul 16, 2026
Company Drug

WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager

Fineline Cube Jan 7, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Drug

Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials

Fineline Cube Jan 7, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced that it has received clinical trial...

Company Deals

Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making

Fineline Cube Jan 7, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially submitted an initial public offering (IPO)...

Company Deals

Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization

Fineline Cube Jan 7, 2025

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a partnership with compatriot firm...

Policy / Regulatory

CDE Announces 90th Batch of Reference Preparations for GQCE

Fineline Cube Jan 7, 2025

China’s Center for Drug Evaluation (CDE) has selected the 90th batch of reference preparations for...

Company Deals Drug

Solasia Pharma Licenses Episil to GeneScience for Greater China Region

Fineline Cube Jan 7, 2025

Japan-based Solasia Pharma K. K (TYO: 4597) has announced a licensing agreement with Changchun GeneScience...

Company Deals

Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines

Fineline Cube Jan 7, 2025

Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...

Company Drug

GSK’s Nucala Receives New Indication Approval in China for CRSwNP

Fineline Cube Jan 6, 2025

UK-based pharmaceutical company GlaxoSmithKline’s (GSK; NYSE: GSK) has announced that it has received another indication...

Policy / Regulatory

China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access

Fineline Cube Jan 6, 2025

The healthcare security administration bureaus in Shanghai, Beijing, and other regions have recently removed limits...

Company Deals

Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau

Fineline Cube Jan 6, 2025

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...

Company Deals Medical Device

Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development

Fineline Cube Jan 6, 2025

China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to...

Company Deals

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round

Fineline Cube Jan 6, 2025

China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C...

Company Drug

Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...

Company Deals

Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services

Fineline Cube Jan 6, 2025

China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical...

Company Medical Device

Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received...

Company Drug

MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study

Fineline Cube Jan 6, 2025

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received approval from...

Company Drug

Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA

Fineline Cube Jan 6, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial

Fineline Cube Jan 6, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...

Policy / Regulatory

China’s State Council Aims to Enhance Drug and Medical Device Regulation by 2027

Fineline Cube Jan 6, 2025

China’s State Council has released the “Opinions on Fully Deepening the Reform of Drug and...

Company

Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding

Fineline Cube Jan 5, 2025

Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a...

Posts pagination

1 … 263 264 265 … 695

Recent updates

  • Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management
  • Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
  • Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
  • WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
  • China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.